Article Details
Retrieved on: 2022-11-20 16:19:38
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Wedbush reduced their price target on shares of Kinnate Biopharma to $29.00 in a report on Wednesday. One equities research analyst has rated the ...
Article found on: www.etfdailynews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here